PBAC's latest decision on Tenofovir disoproxil fumarate with emtricitabine / tenofovir disoproxil maleate with emtricitabine / tenofovir disoproxil phosphate with emtricitabine: Recommended with restriction (2020). Considered for Pre-exposure prophylaxis (PrEP) against HIV infection in individuals at risk of acquiring HIV.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Individuals at risk of HIV infection, including men who have sex with men (MSM), Indigenous populations, overseas-born MSM, and heterosexuals; no specific risk classification required under revised criteria.
Therapy area
Infectious disease
Line of therapy
First-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Not applicable
Economic model
Cost-minimisation
Budget impact
$30M
Eligible patients/year
26,360
ICER note
No ICER calculated in this submission. This is a consideration of changed PBS prescribing criteria for an already-listed drug. PBAC noted the Kirby Institute model from December 2017 showed cost-effectiveness below $30,000 per QALY in all scenarios at current price ($1,355 annual cost).